[
  {
    "ts": null,
    "headline": "Is AbbVie a Millionaire Maker?",
    "summary": "AbbVie's third-quarter earnings were disappointing, but the company raised its full-year guidance and increased the dividend.",
    "url": "https://finnhub.io/api/news?id=c0429dbc47af3389d944e95065d4f0364b7c0718dfdee36870dd1cef3888813e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766094600,
      "headline": "Is AbbVie a Millionaire Maker?",
      "id": 137831397,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie's third-quarter earnings were disappointing, but the company raised its full-year guidance and increased the dividend.",
      "url": "https://finnhub.io/api/news?id=c0429dbc47af3389d944e95065d4f0364b7c0718dfdee36870dd1cef3888813e"
    }
  },
  {
    "ts": null,
    "headline": "Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors",
    "summary": "FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the appointment of Adrian Bot, M.D., Ph.D., to the Company’s Board of Directors. Dr. Bot is a biopharma executive with three decades of experience in research and development (R&D) with a focus on immune, cell, gene therapy and nanomedicines. He will serve as a member of the Science a",
    "url": "https://finnhub.io/api/news?id=6f7afe594776c34fa49cc5054dcbb7619f71d17255355f895d9f89a04c53d1fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766091900,
      "headline": "Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors",
      "id": 137825248,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the appointment of Adrian Bot, M.D., Ph.D., to the Company’s Board of Directors. Dr. Bot is a biopharma executive with three decades of experience in research and development (R&D) with a focus on immune, cell, gene therapy and nanomedicines. He will serve as a member of the Science a",
      "url": "https://finnhub.io/api/news?id=6f7afe594776c34fa49cc5054dcbb7619f71d17255355f895d9f89a04c53d1fa"
    }
  },
  {
    "ts": null,
    "headline": "The 3 Income ETFs I’d Use to Offset Social Security",
    "summary": "If you are depending on Social Security for your retirement income, you might want to add reinforcements. While Social Security is tweaked annually in an attempt to keep up with the pace of inflation, its buying power has been dwindling in recent decades while the core inflation rate of 3% continues to hover above the ... The 3 Income ETFs I’d Use to Offset Social Security",
    "url": "https://finnhub.io/api/news?id=8a8323efe3f616ea93a1674e8ca57e1757a1fc80fd9111e0daa425153dfbad87",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766080033,
      "headline": "The 3 Income ETFs I’d Use to Offset Social Security",
      "id": 137825155,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "If you are depending on Social Security for your retirement income, you might want to add reinforcements. While Social Security is tweaked annually in an attempt to keep up with the pace of inflation, its buying power has been dwindling in recent decades while the core inflation rate of 3% continues to hover above the ... The 3 Income ETFs I’d Use to Offset Social Security",
      "url": "https://finnhub.io/api/news?id=8a8323efe3f616ea93a1674e8ca57e1757a1fc80fd9111e0daa425153dfbad87"
    }
  },
  {
    "ts": null,
    "headline": "3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment",
    "summary": "J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.",
    "url": "https://finnhub.io/api/news?id=5726ca2ccdc787ed320a3850e679a9b9333a7f4ca24f8d2b6ffb615ba7be8661",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766072400,
      "headline": "3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment",
      "id": 137825231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.",
      "url": "https://finnhub.io/api/news?id=5726ca2ccdc787ed320a3850e679a9b9333a7f4ca24f8d2b6ffb615ba7be8661"
    }
  }
]